Dynavax Technologies Corp (DVAX)
11.42
-0.34
(-2.89%)
USD |
NASDAQ |
Apr 24, 16:00
11.42
0.00 (0.00%)
After-Hours: 20:00
Dynavax Technologies Enterprise Value: 972.02M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 972.02M |
| April 23, 2024 | 1.016B |
| April 22, 2024 | 1.027B |
| April 19, 2024 | 1.022B |
| April 18, 2024 | 961.57M |
| April 17, 2024 | 973.32M |
| April 16, 2024 | 981.16M |
| April 15, 2024 | 1.007B |
| April 12, 2024 | 1.027B |
| April 11, 2024 | 1.049B |
| April 10, 2024 | 1.041B |
| April 09, 2024 | 1.050B |
| April 08, 2024 | 1.054B |
| April 05, 2024 | 1.054B |
| April 04, 2024 | 1.058B |
| April 03, 2024 | 1.073B |
| April 02, 2024 | 1.088B |
| April 01, 2024 | 1.124B |
| March 28, 2024 | 1.101B |
| March 27, 2024 | 1.101B |
| March 26, 2024 | 1.096B |
| March 25, 2024 | 1.113B |
| March 22, 2024 | 1.086B |
| March 21, 2024 | 1.069B |
| March 20, 2024 | 1.061B |
| Date | Value |
|---|---|
| March 19, 2024 | 1.050B |
| March 18, 2024 | 1.009B |
| March 15, 2024 | 1.054B |
| March 14, 2024 | 1.050B |
| March 13, 2024 | 1.070B |
| March 12, 2024 | 1.131B |
| March 11, 2024 | 1.174B |
| March 08, 2024 | 1.197B |
| March 07, 2024 | 1.155B |
| March 06, 2024 | 1.143B |
| March 05, 2024 | 1.122B |
| March 04, 2024 | 1.144B |
| March 01, 2024 | 1.147B |
| February 29, 2024 | 1.135B |
| February 28, 2024 | 1.172B |
| February 27, 2024 | 1.177B |
| February 26, 2024 | 1.197B |
| February 23, 2024 | 1.146B |
| February 22, 2024 | 1.105B |
| February 21, 2024 | 1.108B |
| February 20, 2024 | 1.084B |
| February 16, 2024 | 1.088B |
| February 15, 2024 | 1.097B |
| February 14, 2024 | 1.097B |
| February 13, 2024 | 1.072B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
211.41M
Minimum
Jul 30 2019
2.318B
Maximum
Nov 03 2021
958.61M
Average
1.011B
Median
Apr 11 2022
Enterprise Value Benchmarks
| Supernus Pharmaceuticals Inc | 1.401B |
| Ligand Pharmaceuticals Inc | 1.087B |
| Pacira BioSciences Inc | 1.448B |
| Esperion Therapeutics Inc | 573.51M |
| PetIQ Inc | 814.50M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.219M |
| Revenue (Quarterly) | 55.60M |
| Total Expenses (Quarterly) | 64.09M |
| Gross Profit Margin (Quarterly) | 84.37% |
| Profit Margin (Quarterly) | 0.39% |
| Earnings Yield | -0.53% |
| Normalized Earnings Yield | 0.0956 |